Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Bod seeks to register its cannabis extract as food in the UK

  • In News
  • February 21, 2022
  • Samantha Freidin
Bod seeks to register its cannabis extract as food in the UK

Cannabis is having a major moment these past few years, trending in research and trickling down into the retail sector. 

Medicinal cannabis company Bod Australia (ASX: BOD) has been selling cannabidiol (CBD) food products within the UK for a while now, however recent legislative changes around the substance dictate that manufacturers now require approval to sell. In response, Bod has submitted a dossier to the United Kingdom’s Food Service Agency to register their proprietary cannabis extract as a food for UK consumers. Approval is expected in the coming months, which will open the doors to further partnerships and expansion of their product range to include new skincare, beverages and pet treat products. 

The Novel Food Registration requires extensive background work on the product including toxicology studies and stability testing. The data garnered from these studies will be used to lodge additional registration applications with the European Union Food Service Agency in coming months. 

Bod has an established presence in the UK, currently selling medicinal cannabis under the name MediCabilis which is available with a prescription. The Company also sells an additional 15 CBD based wellness products through global partner Health and Happiness Group under brand names CBII and Swisse. 

Approval to continue the legal sale of their products in the UK, and soon in the EU will allow Bod to significantly expand their global footprint, opening them to future opportunities. 

Bod CEO Jo Patterson commented on the registration, saying: “The ownership of a Novel Food Registration adds significant value to the exclusive extract Bod uses across our products in the consumer healthcare market. This step is the result of a significant amount of work over the last 12 months. It is great to have achieved this milestone and we are keen to explore the opportunities it will bring. 

“While there are a wide range of CBD products available in the UK, the recent regulatory changes are anticipated to lead to a consolidation in the sector, as those products without a valid registration will need to cease to sell. The Company has been exploring product range expansion options for some time and multiple verticals have been earmarked for growth.”

Since being legalised in the UK in 2018, medicinal cannabis has only grown in popularity. Forecasters predict that by 2024 there will be 338,000 medicinal cannabis users. The market in the UK alone is expected to generate USD $1.29 billion in revenue per year, by 2024. 

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • asx bod
  • Bod Australia
  • cannabidioil
  • Jo Patterson
  • MediCabilis
  • medicinal cannabis
  • swisse
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.